| Ytd | -9.24% | |
| 1y | 87.23% |
| Open | 9.36 | Prev Close | 9.45 | Low | 9.23 | High | 9.55 | Mkt Cap | 1.45B |
| Vol | 723.95K | Avg Vol | 495.14K | EPS | -1.85 | P/E | N/A | Forward P/E | -4.61 |
| Beta | 1.32 | Short Ratio | 12.80 | Inst. Own | 66.66% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-17 | 50-d Avg | 9.44 | 200-d Avg | 10.03 | 1yr Est | 17.63 |
IMTX News
Immatics N.V. is rated "Buy," downgraded from "Strong Buy," due to partial partnership termination a
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million.
Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company"))), the global leader in pre
Houston, Texas and Tuebingen, Germany, August 25, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or
Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.53) per share which missed the analyst conse
Houston, Texas and Tuebingen, Germany, August 18, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or
Shares of Immatics N.V. (NASDAQ: IMTX - Get Free Report) have been assigned a consensus recommendati
Houston, Texas and Tuebingen, Germany, July 17, 2026 - Immatics N. V. (NASDAQ: IMTX, "Immatics" or t
Immatics is evolving into a PRAME-focused oncology platform with three monetization paths, not just
One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, de
One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, de
IMA401 achieved deep and durable responses in various indications, including melanoma and head and n
One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expans
Immatics (IMTX) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate
Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.50) per share which missed the analyst conse
SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggere
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the co
Houston, Texas and Tuebingen, Germany, April 21, 2026 - Immatics N. V. (NASDAQ: IMTX, "Immatics" or
Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in prec
Individual experimental treatment attempt at Hopp Children's Cancer Center Heidelberg (KiTZ) and Hei
SG Americas Securities LLC acquired a new stake in shares of Immatics N.V. (NASDAQ: IMTX) in the fou
Shares of Immatics N.V. (NASDAQ: IMTX - Get Free Report) have earned a consensus recommendation of "
Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.34) per share which beat the analyst consens
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday
On Wednesday, 807 companies reached new 52-week lows.
On Wednesday, 90 companies set new 52-week lows.
During Tuesday's session, 454 stocks hit new 52-week lows.
On Monday, 671 companies achieved new lows for the year.
On Friday, 368 stocks hit new 52-week lows.
On Wednesday, 348 companies hit new 52-week lows.
During Tuesday's trading, 505 companies set new 52-week lows.
On Friday, 313 companies hit new 52-week lows.
During Monday's session, 291 companies made new 52-week lows. Also check out this: Insid
On Tuesday, 88 companies set new 52-week lows.
Wednesday morning saw 162 companies set new 52-week highs.
Gainers Orbital Energy Group, Inc. (NASDAQ: OEG) shares rose 132.3% to $1.94 in pre-market tradi
An ETF based on special purpose acquisition companies that trades on a U.S. exchange is now availabl